Keyword: vitamin D deficiency

The assessment of the vitamin D deficiency between the patients with acute coronary syndrome and those with stable coronary artery disease in a military hospital Morteza Khodaparast1

Background: A few studies compared the vitamin D deficiency condition between the patients with the acute coronary syndrome (ACS) and those with stable coronary artery disease. The present comparative study aimed to assess the vitamin D deficiency status between the patients with ACS and those with stable coronary artery disease. Methods: This cross-sectional study was performed on 200 consecutive patients with the diagnosis of ACS or stable coronary artery disease. Serum Vitamin D level was measured by immunoassay and its serum level was categorized as normal (> 30 ng/ml), insufficient (20 to 30 ng/ml), and deficient (< 20 ng/ml). Results: Overall, 103 patients were categorized as stable angina group, 74 had unstable angina, 10 had STEMI, and 13 had NSTEMI. There was no difference in serum vitamin D3 level across the four groups including stable angina group (13.81 ± 15.13 ng/ml), unstable angina group (15.13 ± 11.11 ng/ml), STEMI group (21.58 ± 19.87 ng/ml), and NSTEMI group (18.67 ± 13.07 ng/ml) (p = 0.276). No difference was also found in the mean vitamin D3 level between the groups with new MI (15.98 ± 12.44 ng/ml versus 14.01 ± 15.31 ng/ml, p = 0.318). In total, 8.5% had normal vitamin D levels and 9.0% had vitamin D insufficiency, while the majority of patients (82.5%) were vitamin D deficient. The vitamin D deficiency was comparable in the patients with stable angina compared to those in ACS groups. According to ROC curve analysis, measuring serum vitamin D3 had a moderate value to discriminate stable angina from ACS (AUC = 0.651). In this regard, the best cutoff point for serum vitamin D3 level to discriminate stable angina from ACS was 9.0 ng/ml yielding a sensitivity of 70.1% and a specificity of 57.3%. Conclusion: The measurement of vitamin D and thus the presence of vitamin D deficiency have no sufficient power to discriminate ACS from stable coronary artery disease

Vitamin D status and cholecalciferol supplementation on patients with active Basedow disease: a clinical study

This study aims to analyze the 25-hydroxyvitamin D (25OHD) corelations with TRab (anti-TSH receptor Antibodies) at baseline and after corections of 25OHD deficit. Method: Prospective, interventional, controled, single-centre, clinical study on 62 patients with active Basedow disease (BD), admitted at C.I. Parhon National Institute of Endocrinology, Bucharest, Romania, between 2013 and 2020. Patients were divided into two groups: one group (N=37) received 2000 IU of daily cholecalciferol and a second one (N=25) without vitamin D supplementation, all subjects being under anti-thyroid drugs (standard guideline therapy). 25OHD and TRab levels were assessed at start and after 6, respective 12 months. Results: Initial evaluation confirmed vitamin D deficiency (mean 25OHD of 18.33±6.45 ng/mL). At start, TRab negatively correlates with 25OHD (N=62, r= -0.22, p=0.08). The decrease in TRab was statistically significant higher in group 1 versus group 2 after 6 months (35.84% versus 3.53%, p=0.03). After 12 months, TRab decreased with 56.28% in group 1, respective 27.16% in group 2 (p=0.03). In group 1, inverse correlation between 25OHD and TRab was consistent at 6 and 12 months. Conclusion: In patients with active BD, TRab values were negatively correlated with 25OHD at baseline and during follow-up. Correction of vitamin D deficiency is correlated with the decrease of TRab levels.